ReviewFrontiers in artificial intelligence2025
Artificial intelligence-assisted capsule endoscopy for detecting lesions in Crohn's disease: a systematic review and meta-analysis.
Review in Frontiers in artificial intelligence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Objective Endoscopic Assessment for Prediction of Secondary Loss of Response of Biologics in Crohn's Disease.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2026Article
- Artificial intelligence in inflammatory bowel disease: From current evidence, clinical translation, and the road to precision medicine.Chinese medical journal · 2026Review
- Advances in Artificial Intelligence for Gastrointestinal Endoscopy: 2026 Update.Diagnostics (Basel, Switzerland) · 2026Review
- Current approaches to disease severity and therapy effectiveness assessment in patients with inflammatory bowel disease.World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- Artificial intelligence in inflammatory bowel disease: bridging innovation, implementation and impact.Nature reviews. Gastroenterology & hepatology · 2026Review
- New Technologies for IBD Endoscopy.Journal of clinical medicine · 2026Review
- Artificial intelligence and digital transformation of gastroenterology and hepatology: A critical review of clinical applications and future challenges.World journal of hepatology · 2026Review
- [Risks and benefits of artificial intelligence in luminal endoscopy].Innere Medizin (Heidelberg, Germany) · 2026Review
- Artificial Intelligence-Based Localization of Small Bowel Anatomic Transition Zones in Crohn's Disease Using Capsule Endoscopy.Endoscopy international open · 2026Article
- Subclass-Aware Contrastive Semi-Supervised Learning for Inflammatory Bowel Disease Classification from Colonoscopy Images.Bioengineering (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: Crohn's disease (CD), a complex member of the inflammatory bowel disease spectrum, is characterized by the diversity and skipping distribution of intestinal mucosal lesions, significantly complicating its differential diagnosis with intestinal diseases such as ulcerative colitis and intestinal tuberculosis. With the increasing application of artificial intelligence (AI) in the medical field, its utilization in primary diagnosis has become more widespread. However, there is a lack of systematic evaluation regarding the specific efficacy of AI in identifying CD through capsule endoscopy. Methods: This study conducted a comprehensive search of PubMed databases, Cochrane, EMBASE, and Web of Science up to May 21, 2024, to collect relevant literature. The Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool was used to rigorously assess the quality of included studies, and detailed information on study characteristics and AI algorithms was extracted. A bivariate mixed-effects model was employed to synthesize and analyze the sensitivity, specificity, and area under the receiver operating characteristic curve (AUC). Additionally, meta-regression and subgroup analyses were conducted to delve into the potential sources of heterogeneity. Results: Ultimately, eight studies encompassing 11 distinct AI models were included in this meta-analysis. The overall area under the curve (AUC) for AI in identifying CD through capsule endoscopy was 99% (95% CI, 100%-0.00), indicating high diagnostic accuracy. Specifically, the pooled sensitivity was 94% (95% CI, 93-96%), specificity was 97% (95% CI, 95-98%), positive likelihood ratio (PLR) was 32.7 (95% CI, 19.9-53.6), negative likelihood ratio (NLR) was 6% (95% CI, 4-7%), and diagnostic odds ratio (DOR) reached 576 (95% CI, 295-1,127). Meta-regression analysis further revealed that AI algorithm type, study population size, and study design might be key sources of heterogeneity. Conclusion: This study demonstrates the significant potential of AI technology in assisting endoscopists in detecting and identifying CD patients through capsule endoscopy. However, given the limitations and heterogeneity of current research, more high-quality, large-sample studies are needed to comprehensively and thoroughly evaluate the practical application value of AI in CD diagnosis, thereby promoting its widespread adoption and optimization in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.